JY231 Injection for the Treatment of B-cell Malignancies Early Exploratory Clinical Studies on Safety, Tolerability, and Initial Efficacy
Latest Information Update: 28 Jul 2025
At a glance
- Drugs JY 231 (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 28 Jul 2025 New trial record